Targeting extrinsic apoptosis in cancer: Challenges and opportunities

Seminars in Cell and Developmental Biology

Volumn 39, Issue , 2015, Pages 20-25

  Fulda, Simone ^a,b  

^a GOETHE UNIVERSITY   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Apoptosis; Cancer; Caspase 8; TRAIL

Indexed keywords

CASPASE 8; DEATH RECEPTOR; FLICE INHIBITORY PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER THERAPY; EXTRACELLULAR SPACE; HUMAN; INTRACELLULAR SIGNALING; NEOPLASM; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; NEOPLASMS;

ANIMALS; APOPTOSIS; HUMANS; NEOPLASMS; RECEPTORS, DEATH DOMAIN; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84928212128     PISSN: 10849521     EISSN: 10963634     Source Type: Journal    
DOI: 10.1016/j.semcdb.2015.01.006     Document Type: Review

References (87)

1. Lockshin R.A., Zakeri Z. Cell death in health and disease. J Cell Mol Med 2007, 11:1214-1224.
2. Galluzzi L., Vitale I., Abrams J.M., Alnemri E.S., Baehrecke E.H., Blagosklonny M.V., et al. Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ 2012, 19:107-120.
3. Fulda S. Tumor resistance to apoptosis. Int J Cancer 2009, 124:511-515.
4. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
5. Fulda S., Debatin K.M. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 2006, 25:4798-4811.
6. Ashkenazi A. Targeting the extrinsic apoptosis pathway in cancer. Cytokine Growth Factor Rev 2008, 19:325-331.
7. Fulda S., Galluzzi L., Kroemer G. Targeting mitochondria for cancer therapy. Nat Rev Drug Discov 2010, 9:447-464.
8. Riedl S.J., Salvesen G.S. The apoptosome: signalling platform of cell death. Nat Rev Mol Cell Biol 2007, 8:405-413.
9. Fulda S., Vucic D. Targeting IAP proteins for therapeutic intervention in cancer. Nat Rev Drug Discov 2012, 11:109-124.
10. Taylor R.C., Cullen S.P., Martin S.J. Apoptosis: controlled demolition at the cellular level. Nat Rev Mol Cell Biol 2008, 9:231-241.
11. Fulda S. Targeting c-FLICE-like inhibitory protein (CFLAR) in cancer. Expert Opin Ther Targets 2013, 17:195-201.
12. Fulda S. The dark side of TRAIL signaling. Cell Death Differ 2013, 20:845-846.
13. Chamuleau M.E., Ossenkoppele G.J., van Rhenen A., van Dreunen L., Jirka S.M., Zevenbergen A., et al. High TRAIL-R3 expression on leukemic blasts is associated with poor outcome and induces apoptosis-resistance which can be overcome by targeting TRAIL-R2. Leuk Res 2011, 35:741-749.
14. Lalaoui N., Morle A., Merino D., Jacquemin G., Iessi E., Morizot A., et al. TRAIL-R4 promotes tumor growth and resistance to apoptosis in cervical carcinoma HeLa cells through AKT. PLoS ONE 2011, 6:e19679.
15. Meng R.D., McDonald E.R., Sheikh M.S., Fornace A.J., El-Deiry W.S. The TRAIL decoy receptor TRUNDD (DcR2, TRAIL-R4) is induced by adenovirus-p53 overexpression and can delay TRAIL-, p53-, and KILLER/DR5-dependent colon cancer apoptosis. Mol Ther 2000, 1:130-144.
16. Merino D., Lalaoui N., Morizot A., Schneider P., Solary E., Micheau O. Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. Mol Cell Biol 2006, 26:7046-7055.
17. Pai S.I., Wu G.S., Ozoren N., Wu L., Jen J., Sidransky D., et al. Rare loss-of-function mutation of a death receptor gene in head and neck cancer. Cancer Res 1998, 58:3513-3518.
18. Dechant M.J., Fellenberg J., Scheuerpflug C.G., Ewerbeck V., Debatin K.M. Mutation analysis of the apoptotic "death-receptors" and the adaptors TRADD and FADD/MORT-1 in osteosarcoma tumor samples and osteosarcoma cell lines. Int J Cancer 2004, 109:661-667.
19. Jin Z., McDonald E.R., Dicker D.T., El-Deiry W.S. Deficient tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor transport to the cell surface in human colon cancer cells selected for resistance to TRAIL-induced apoptosis. J Biol Chem 2004, 279:35829-35839.
20. Elias A., Siegelin M.D., Steinmuller A., von Deimling A., Lass U., Korn B., et al. Epigenetic silencing of death receptor 4 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in gliomas. Clin Cancer Res 2009, 15:5457-5465.
21. Horak P., Pils D., Haller G., Pribill I., Roessler M., Tomek S., et al. Contribution of epigenetic silencing of tumor necrosis factor-related apoptosis inducing ligand receptor 1 (DR4) to TRAIL resistance and ovarian cancer. Mol Cancer Res 2005, 3:335-343.
22. Chow L.Q., Eckhardt S.G., Gustafson D.L., O'Bryant C., Hariharan S., Diab S., et al. HGS-ETR1, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase 1 and PK study. J Clin Oncol 2006, 24:2515.
23. Patnaik A., Wakelee H., Mita M., Fitzgerald A., Hill M., Fox N., et al. HGS-ETR2 - a fully human monoclonal antibody to TRAIL-R2: results of a phase I trial in patients with advanced solid tumors. Proceedings Am Soc Clin Oncol 42nd annual meeting, A 2006, 3012.
24. Tolcher A.W., Mita M., Meropol N.J., von Mehren M., Patnaik A., Padavic K., et al. Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. J Clin Oncol 2007, 25:1390-1395.
25. Herbst R.S., Mendolson D.S., Ebbinghaus S., Gordon M.S., O'Dwyer P., Lieberman G., et al. A phase I safety and pharmacokinetic (PK) study of recombinant Apo2L/TRAIL, an apoptosis-inducing protein in patients with advanced cancer. J Clin Oncol 2006, 24:3013.
26. Gieffers C., Kluge M., Merz C., Sykora J., Thiemann M., Schaal R., et al. APG350 induces superior clustering of TRAIL receptors and shows therapeutic antitumor efficacy independent of cross-linking via Fcgamma receptors. Mol Cancer Ther 2013, 12:2735-2747.
27. Lacour S., Micheau O., Hammann A., Drouineaud V., Tschopp J., Solary E., et al. Chemotherapy enhances TNF-related apoptosis-inducing ligand DISC assembly in HT29 human colon cancer cells. Oncogene 2003, 22:1807-1816.
28. Morizot A., Merino D., Lalaoui N., Jacquemin G., Granci V., Iessi E., et al. Chemotherapy overcomes TRAIL-R4-mediated TRAIL resistance at the DISC level. Cell Death Differ 2011, 18:700-711.
29. Nagane M., Pan G., Weddle J.J., Dixit V.M., Cavenee W.K., Huang H.J. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. Cancer Res 2000, 60:847-853.
30. Sheikh M.S., Burns T.F., Huang Y., Wu G.S., Amundson S., Brooks K.S., et al. P53-dependent and -independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor alpha. Cancer Res 1998, 58:1593-1598.
31. Sheikh M.S., Huang Y., Fernandez-Salas E.A., El-Deiry W.S., Friess H., Amundson S., et al. The antiapoptotic decoy receptor TRID/TRAIL-R3 is a p53-regulated DNA damage-inducible gene that is overexpressed in primary tumors of the gastrointestinal tract. Oncogene 1999, 18:4153-4159.
32. Singh T.R., Shankar S., Chen X., Asim M., Srivastava R.K. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo. Cancer Res 2003, 63:5390-5400.
33. Wang S., El-Deiry W.S. Requirement of p53 targets in chemosensitization of colonic carcinoma to death ligand therapy. Proc Natl Acad Sci U S A 2003, 100:15095-15100.
34. Liu X., Yue P., Chen S., Hu L., Lonial S., Khuri F.R., et al. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells. Cancer Res 2007, 67:4981-4988.
35. Nagy K., Szekely-Szuts K., Izeradjene K., Douglas L., Tillman M., Barti-Juhasz H., et al. Proteasome inhibitors sensitize colon carcinoma cells to TRAIL-induced apoptosis via enhanced release of Smac/DIABLO from the mitochondria. Pathol Oncol Res 2006, 12:133-142.
36. Naumann I., Kappler R., von Schweinitz D., Debatin K.M., Fulda S. Bortezomib primes neuroblastoma cells for TRAIL-induced apoptosis by linking the death receptor to the mitochondrial pathway. Clin Cancer Res 2011, 17:3204-3218.
37. Nikrad M., Johnson T., Puthalalath H., Coultas L., Adams J., Kraft A.S. The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim. Mol Cancer Ther 2005, 4:443-449.
38. Rohn T.A., Wagenknecht B., Roth W., Naumann U., Gulbins E., Krammer P.H., et al. CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release. Oncogene 2001, 20:4128-4137.
39. Sayers T.J., Brooks A.D., Koh C.Y., Ma W., Seki N., Raziuddin A., et al. The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP. Blood 2003, 102:303-310.
40. Shanker A., Brooks A.D., Tristan C.A., Wine J.W., Elliott P.J., Yagita H., et al. Treating metastatic solid tumors with bortezomib and a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist antibody. J Natl Cancer Inst 2008, 100:649-662.
41. Unterkircher T., Cristofanon S., Vellanki S.H., Nonnenmacher L., Karpel-Massler G., Wirtz C.R., et al. Bortezomib primes glioblastoma, including glioblastoma stem cells, for TRAIL by increasing tBid stability and mitochondrial apoptosis. Clin Cancer Res 2011, 17:4019-4030.
42. Muhlethaler-Mottet A., Flahaut M., Bourloud K.B., Auderset K., Meier R., Joseph J.M., et al. Histone deacetylase inhibitors strongly sensitise neuroblastoma cells to TRAIL-induced apoptosis by a caspases-dependent increase of the pro- to anti-apoptotic proteins ratio. BMC Cancer 2006, 6:214.
43. Nakata S., Yoshida T., Horinaka M., Shiraishi T., Wakada M., Sakai T. Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells. Oncogene 2004, 23:6261-6271.
44. Neuzil J., Swettenham E., Gellert N. Sensitization of mesothelioma to TRAIL apoptosis by inhibition of histone deacetylase: role of Bcl-xL down-regulation. Biochem Biophys Res Commun 2004, 314:186-191.
45. Pathil A., Armeanu S., Venturelli S., Mascagni P., Weiss T.S., Gregor M., et al. HDAC inhibitor treatment of hepatoma cells induces both TRAIL-independent apoptosis and restoration of sensitivity to TRAIL. Hepatology 2006, 43:425-434.
46. Reddy R.M., Yeow W.S., Chua A., Nguyen D.M., Baras A., Ziauddin M.F., et al. Rapid and profound potentiation of Apo2L/TRAIL-mediated cytotoxicity and apoptosis in thoracic cancer cells by the histone deacetylase inhibitor Trichostatin A: the essential role of the mitochondria-mediated caspase activation cascade. Apoptosis 2007, 12:55-71.
47. Schuchmann M., Schulze-Bergkamen H., Fleischer B., Schattenberg J.M., Siebler J., Weinmann A., et al. Histone deacetylase inhibition by valproic acid down-regulates c-FLIP/CASH and sensitizes hepatoma cells towards CD95- and TRAIL receptor-mediated apoptosis and chemotherapy. Oncol Rep 2006, 15:227-230.
48. Haag C., Stadel D., Zhou S., Bachem M.G., Moller P., Debatin K.M., et al. Identification of c-FLIP(L) and c-FLIP(S) as critical regulators of death receptor-induced apoptosis in pancreatic cancer cells. Gut 2011, 60:225-237.
49. Feoktistova M., Geserick P., Kellert B., Dimitrova D.P., Langlais C., Hupe M., et al. cIAPs block ripoptosome formation, a RIP1/caspase-8 containing intracellular cell death complex differentially regulated by cFLIP isoforms. Mol Cell 2011, 43:449-463.
50. Vanden Berghe T., Linkermann A., Jouan-Lanhouet S., Walczak H., Vandenabeele P. Regulated necrosis: the expanding network of non-apoptotic cell death pathways. Nat Rev Mol Cell Biol 2014, 15:135-147.
51. Oberst A., Dillon C.P., Weinlich R., McCormick L.L., Fitzgerald P., Pop C., et al. Catalytic activity of the caspase-8-FLIP(L) complex inhibits RIPK3-dependent necrosis. Nature 2011, 471:363-367.
52. Fulda S., Meyer E., Debatin K.M. Metabolic inhibitors sensitize for CD95 (APO-1/Fas)-induced apoptosis by down-regulating Fas-associated death domain-like interleukin 1-converting enzyme inhibitory protein expression. Cancer Res 2000, 60:3947-3956.
53. Panner A., James C.D., Berger M.S., Pieper R.O. mTOR controls FLIPS translation and TRAIL sensitivity in glioblastoma multiforme cells. Mol Cell Biol 2005, 25:8809-8823.
54. Susin S.A., Lorenzo H.K., Zamzami N., Marzo I., Snow B.E., Brothers G.M., et al. Molecular characterization of mitochondrial apoptosis-inducing factor. Nature 1999, 397:441-446.
55. Bangert A., Cristofanon S., Eckhardt I., Abhari B.A., Kolodziej S., Hacker S., et al. Histone deacetylase inhibitors sensitize glioblastoma cells to TRAIL-induced apoptosis by c-myc-mediated downregulation of cFLIP. Oncogene 2012, 31:4677-4688.
56. Yerbes R., Lopez-Rivas A. Itch/AIP4-independent proteasomal degradation of cFLIP induced by the histone deacetylase inhibitor SAHA sensitizes breast tumour cells to TRAIL. Invest New Drugs 2012, 30:541-547.
57. Kerr E., Holohan C., McLaughlin K.M., Majkut J., Dolan S., Redmond K., et al. Identification of an acetylation-dependant Ku70/FLIP complex that regulates FLIP expression and HDAC inhibitor-induced apoptosis. Cell Death Differ 2012, 19:1317-1327.
58. Zou W., Liu X., Yue P., Khuri F.R., Sun S.Y. PPARgamma ligands enhance TRAIL-induced apoptosis through DR5 upregulation and c-FLIP downregulation in human lung cancer cells. Cancer Biol Ther 2007, 6:99-106.
59. Kim Y.H., Jung E.M., Lee T.J., Kim S.H., Choi Y.H., Park J.W., et al. Rosiglitazone promotes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by reactive oxygen species-mediated up-regulation of death receptor 5 and down-regulation of c-FLIP. Free Radic Biol Med 2008, 44:1055-1068.
60. Kinoshita H., Yoshikawa H., Shiiki K., Hamada Y., Nakajima Y., Tasaka K. Cisplatin (CDDP) sensitizes human osteosarcoma cell to Fas/CD95-mediated apoptosis by down-regulating FLIP-L expression. Int J Cancer 2000, 88:986-991.
61. Abedini M.R., Muller E.J., Brun J., Bergeron R., Gray D.A., Tsang B.K. Cisplatin induces p53-dependent FLICE-like inhibitory protein ubiquitination in ovarian cancer cells. Cancer Res 2008, 68:4511-4517.
62. Fulda S. Caspase-8 in cancer biology and therapy. Cancer Lett 2009, 281:128-133.
63. Kim H.S., Lee J.W., Soung Y.H., Park W.S., Kim S.Y., Lee J.H., et al. Inactivating mutations of caspase-8 gene in colorectal carcinomas. Gastroenterology 2003, 125:708-715.
64. Mandruzzato S., Brasseur F., Andry G., Boon T., Van der Bruggen P. A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma. J Exp Med 1997, 186:785-793.
65. Soung Y.H., Lee J.W., Kim S.Y., Jang J., Park Y.G., Park W.S., et al. CASPASE-8 gene is inactivated by somatic mutations in gastric carcinomas. Cancer Res 2005, 65:815-821.
66. Teitz T., Wei T., Valentine M.B., Vanin E.F., Grenet J., Valentine V.A., et al. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat Med 2000, 6:529-535.
67. Fulda S., Kufer M.U., Meyer E., van Valen F., Dockhorn-Dworniczak B., Debatin K.M. Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogene 2001, 20:5865-5877.
68. Hopkins-Donaldson S., Bodmer J.L., Bourloud K.B., Brognara C.B., Tschopp J., Gross N. Loss of caspase-8 expression in highly malignant human neuroblastoma cells correlates with resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Cancer Res 2000, 60:4315-4319.
69. Grotzer M.A., Eggert A., Zuzak T.J., Janss A.J., Marwaha S., Wiewrodt B.R., et al. Resistance to TRAIL-induced apoptosis in primitive neuroectodermal brain tumor cells correlates with a loss of caspase-8 expression. Oncogene 2000, 19:4604-4610.
70. Eggert A., Grotzer M.A., Zuzak T.J., Wiewrodt B.R., Ho R., Ikegaki N., et al. Resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression. Cancer Res 2001, 61:1314-1319.
71. Van Noesel M.M., Van Bezouw S., Voute P.A., Herman J.G., Pieters R., Versteeg R. Clustering of hypermethylated genes in neuroblastoma. Genes Chromosomes Cancer 2003, 38:226-233.
72. Miller M.A., Karacay B., Zhu X., O'Dorisio M.S., Sandler A.D. Caspase 8L, a novel inhibitory isoform of caspase 8, is associated with undifferentiated neuroblastoma. Apoptosis 2006, 11:15-24.
73. Mohr A., Zwacka R.M., Jarmy G., Buneker C., Schrezenmeier H., Dohner K., et al. Caspase-8L expression protects CD34+ hematopoietic progenitor cells and leukemic cells from CD95-mediated apoptosis. Oncogene 2005, 24:2421-2429.
74. Cursi S., Rufini A., Stagni V., Condo I., Matafora V., Bachi A., et al. Src kinase phosphorylates caspase-8 on Tyr380: a novel mechanism of apoptosis suppression. EMBO J 2006, 25:1895-1905.
75. Furchert S.E., Lanvers-Kaminsky C., Juurgens H., Jung M., Loidl A., Fruhwald M.C. Inhibitors of histone deacetylases as potential therapeutic tools for high-risk embryonal tumors of the nervous system of childhood. Int J Cancer 2007, 120:1787-1794.
76. Kaminskyy V.O., Surova O.V., Vaculova A., Zhivotovsky B. Combined inhibition of DNA methyltransferase and histone deacetylase restores caspase-8 expression and sensitizes SCLC cells to TRAIL. Carcinogenesis 2011, 32:1450-1458.
77. Yang X., Merchant M.S., Romero M.E., Tsokos M., Wexler L.H., Kontny U., et al. Induction of caspase 8 by interferon gamma renders some neuroblastoma (NB) cells sensitive to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but reveals that a lack of membrane TR1/TR2 also contributes to TRAIL resistance in NB. Cancer Res 2003, 63:1122-1129.
78. Casciano I., De Ambrosis A., Croce M., Pagnan G., Di Vinci A., Allemanni G., et al. Expression of the caspase-8 gene in neuroblastoma cells is regulated through an essential interferon-sensitive response element (ISRE). Cell Death Differ 2004, 11:131-134.
79. Ruiz-Ruiz C., Ruiz de Almodovar C., Rodriguez A., Ortiz-Ferron G., Redondo J.M., Lopez-Rivas A. The up-regulation of human caspase-8 by interferon-gamma in breast tumor cells requires the induction and action of the transcription factor interferon regulatory factor-1. J Biol Chem 2004, 279:19712-19720.
80. Fulda S., Debatin K.M. IFNgamma sensitizes for apoptosis by upregulating caspase-8 expression through the Stat1 pathway. Oncogene 2002, 21:2295-2308.
81. Tekautz T.M., Zhu K., Grenet J., Kaushal D., Kidd V.J., Lahti J.M. Evaluation of IFN-gamma effects on apoptosis and gene expression in neuroblastoma - preclinical studies. Biochim Biophys Acta 2006, 1763:1000-1010.
82. Meister N., Shalaby T., von Bueren A.O., Rivera P., Patti R., Oehler C., et al. Interferon-gamma mediated up-regulation of caspase-8 sensitizes medulloblastoma cells to radio- and chemotherapy. Eur J Cancer 2007, 43:1833-1841.
83. Lissat A., Vraetz T., Tsokos M., Klein R., Braun M., Koutelia N., et al. Interferon-gamma sensitizes resistant Ewing's sarcoma cells to tumor necrosis factor apoptosis-inducing ligand-induced apoptosis by up-regulation of caspase-8 without altering chemosensitivity. Am J Pathol 2007, 170:1917-1930.
84. Merchant M.S., Yang X., Melchionda F., Romero M., Klein R., Thiele C.J., et al. Interferon gamma enhances the effectiveness of tumor necrosis factor-related apoptosis-inducing ligand receptor agonists in a xenograft model of Ewing's sarcoma. Cancer Res 2004, 64:8349-8356.
85. Ruiz-Ruiz C., Munoz-Pinedo C., Lopez-Rivas A. Interferon-gamma treatment elevates caspase-8 expression and sensitizes human breast tumor cells to a death receptor-induced mitochondria-operated apoptotic program. Cancer Res 2000, 60:5673-5680.
86. Hacker S., Dittrich A., Mohr A., Schweitzer T., Rutkowski S., Krauss J., et al. Histone deacetylase inhibitors cooperate with IFN-gamma to restore caspase-8 expression and overcome TRAIL resistance in cancers with silencing of caspase-8. Oncogene 2009, 28:3097-3110.
87. Jiang M., Zhu K., Grenet J., Lahti J.M. Retinoic acid induces caspase-8 transcription via phospho-CREB and increases apoptotic responses to death stimuli in neuroblastoma cells. Biochim Biophys Acta 2008, 1783:1055-1067.